BioPharma Resources

Drug Trial Radar · NCT07738107

ATR 1072 in Participants With PRKAG2 Syndrome

A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous ATR 1072 for the Treatment of PRKAG2 Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Sep 14, 2026

Primary completion

May 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Atrium TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.

Conditions

  • Cardiac Glycogenosis
  • Cardiomyopathy
  • Hypertrophic
  • Wolff-Parkinson-White Syndrome

Interventions

  • ATR 1072Drug

    ATR 1072 is an investigational therapy that delivers an siRNA to reduce PRKAG2 gene expression. Administered as an intravenous (IV) infusion every 6 weeks (Q6W). Formulated as a sterile liquid for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From first dose through end of study (approximately 48 weeks per participant)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • St Luke's Mid American Heart Institute

    Kansas City, Missouri · Recruiting

  • Houston Methodist

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.